Cell line · CVCL_2690
Papers39
1 to 20 of 39
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Extracellular vesicle lipidomics liquid biopsy reveals systemic and tumor microenvironment metabolic reprogramming in ovarian cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor Resistance. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer. | Br J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DHX9 Inhibition Enhances Paclitaxel Sensitivity by Inducing Mitotic Failure in Ovarian and Endometrial Cancers. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. | Adv Biol (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Metabolic Dependency on De Novo Pyrimidine Synthesis Is a Targetable Vulnerability in Platinum-Resistant Ovarian Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Homologous recombination promotes non-immunogenic mitotic cell death upon DNA damage. | Nat Cell Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| lncRNA BC200 is processed into a stable Alu monomer. | RNA | 2024 | Its Methods give the RRID and name the line | PubMed | |
| CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade. | Nat Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| BRCA2 Status Alters the Effect of the P53 Reactivator HO-3867 in Ovarian Cancer Cells. | J Cancer Sci Clin Ther | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Fatty Acid Reprogramming Suppresses CARM1-expressing Ovarian Cancer. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer. | Cancer Immunol Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. | Cell Rep Med | 2021 | Cellosaurus cites it, and its Methods give the RRID and name the line | PubMed | |
| The SETDB1-TRIM28 Complex Suppresses Antitumor Immunity. | Cancer Immunol Res | 2021 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_2690/papers